FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine. Described is an anticancer therapeutic agent for combined application of compound of formula (I) or its pharmaceutically acceptable salts, and compound of formula (II): 
, where R1 is C3cycloalkyl, R2 is a hydrogen atom and R3 represents a chlorine atom.
EFFECT: agent exhibits exclusive anticancer effect compared to when the said compounds are used separately.
5 cl, 2 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTICANCER AGENT INVOLVING COMBINATIONS OF KINASE INHIBITORY COMPOUNDS | 2011 |
|
RU2560683C2 |
| THERAPEUTIC AGENT FOR BILIARY TRACT CANCER TREATMENT | 2016 |
|
RU2728932C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING QUINOLINE DERIVATIVE | 2010 |
|
RU2548673C2 |
| ANTICANCER DRUG FOR THYROID CANCER | 2007 |
|
RU2448708C2 |
| CRYSTAL FORM OF 4-(3-CHLORINE-4-(CYCLOPROPYLAMINOCARBONYL)AMINOPHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE SALT OR ITS SOLVATE AND METHODS FOR ITS PRODUCING | 2004 |
|
RU2328489C2 |
| NITROGEN-CONTAINING AROMATIC DERIVATIVES, THEIR USING, MEDICINAL AGENT BASED ON THEREOF AND METHOD FOR TREATMENT | 2001 |
|
RU2264389C2 |
| HIGH-PURITY QUINOLINE DERIVATIVE AND ITS PRODUCTION METHOD | 2015 |
|
RU2785875C2 |
| ANTITUMOUR THERAPEUTIC AGENT | 2016 |
|
RU2718048C2 |
| AGENT INTENSIFYING ACTION OF ANTI-CANCER AGENTS | 2012 |
|
RU2589713C2 |
| COMBINATION THERAPY INCLUDING AN ACYLTHIOUREA COMPOUND AND ABIRATERONE | 2019 |
|
RU2806635C2 |
